Amylyx Pharmaceuticals, Inc.
AMLX evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for AMLX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · AMLX
Amylyx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapies for neurodegenerative and metabolic diseases, with a lead pipeline candidate avexitide for post-bariatric hypoglycemia and ongoing trials for AMX0035 and AMX0114.
Key risk: Clinical-stage pipeline risk
BioSniper Score
Based on 6 of 6 signals
Market Cap
$3.87B
Cash Runway
23.2 moLead Asset
AMX0035 (Phase 2)
Next Catalyst
Phase3_Topline · Feb 1, 2027Financial data as of Jun 30, 2026.
Tracking 4 pipeline candidates · 7 clinical trials · 1 catalyst for Amylyx Pharmaceuticals, Inc..
Amylyx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapies for neurodegenerative and metabolic diseases, with a lead pipeline candidate avexitide for post-bariatric hypoglycemia and ongoing trials for AMX0035 and AMX0114.
- Cash and equivalents of $50.3M as of 2026-06-30 [sec].
- Net loss of $43.4M for the quarter ended 2026-06-30 [sec].
- Shareholders' equity of $167.9M as of 2026-06-30 [sec].
- Accumulated deficit of $836.1M as of 2026-06-30 [sec_mda].
- Management believes existing cash will fund operations into 2028 [sec_mda].
What works
- Cash runway extended into 2028, providing a multi-year development horizon without near-term financing pressure [sec_mda].
- Multiple pipeline candidates in clinical development (avexitide, AMX0035, AMX0114) diversifying risk across indications [sec_mda].
What to weigh
- Significant accumulated deficit of $836.1M as of 2026-06-30, reflecting years of R&D spending without a marketed product [sec_mda].
- Net loss of $43.4M in the most recent quarter, indicating ongoing cash burn [sec].
- All pipeline candidates are still in clinical stages; no approved product generating revenue [sec_mda].
From the filings
Quoted directly from source documents.
Cash position and runway
“$250.8 million and an accumulated deficit of $836.1 million. We believe our existing cash, cash equivalents and marketable securities as of June 30, 2026 will be sufficient to fund our operations into 2028.”
SEC MD&A · August 6, 2026
Catalyst timeline
- 2027-02-01 · Phase3_Topline · post-bariatric — Topline results from a Phase 3 randomized, double-blind, placebo-controlled study of avexitide in post-bariatric hypoglycemia.
Risks & what to watch (3)›
Key risks
- Clinical-stage pipeline risk — All product candidates are in clinical trials; no approved products generating revenue [sec_mda].
- Cash burn and accumulated deficit — Net loss of $43.4M and accumulated deficit of $836.1M as of 2026-06-30 [sec, sec_mda].
- Dependence on single candidate — Avexitide is the most advanced pipeline asset; failure would significantly impact the company [sec_mda].
What to watch
- Phase 3 topline data for avexitide in post-bariatric hypoglycemia expected around 2027-02-01 [catalyst].
- Progress of Phase 2 trial of AMX0035 in Wolfram syndrome [sec_mda].
- Any updates from the Phase 1 trial of AMX0114 [sec_mda].
- Cash runway updates in future quarterly filings [sec_mda].
Sources: SEC MD&A · Generated August 26, 2026 · How we verify sources →
Run Amylyx Pharmaceuticals, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Amylyx Pharmaceuticals, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 6 of 6 signals · derived from public data
23.2 months
D/E 0.11 · 0% dilution
Lead: Phase 3
4 candidates
1 upcoming, next in ~155d
1 buy · 2 sells (180d)
Runway
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
170
Total value held
$1.66B
| Holder | Shares | Value |
|---|---|---|
| fmr llc | 16,630,541 | $231.2M |
| perceptive advisors llc | 16,569,764 | $230.3M |
| janus henderson group plc | 9,972,146 | $138.5M |
| blackrock, inc. | 8,828,836 | $122.7M |
| vanguard capital management llc | 8,283,150 | $115.1M |
| commodore capital lp | 5,650,000 | $78.5M |
| adage capital partners gp, l.l.c. | 3,560,764 | $49.5M |
| driehaus capital management llc | 2,987,147 | $41.5M |
| goldman sachs group inc | 2,625,991 | $36.5M |
| state street corp | 2,363,161 | $32.8M |
Showing top 10 of 170 institutional holders of Amylyx Pharmaceuticals, Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 20, 2026- % of float
- 17.2%
- Days to cover
- 13.1
- Shares short
- 14,800,969
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
AMLX short interestGovernance
Frequently asked questions
What is the AI investment thesis for Amylyx Pharmaceuticals, Inc.?
Amylyx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapies for neurodegenerative and metabolic diseases, with a lead pipeline candidate avexitide for post-bariatric hypoglycemia and ongoing trials for AMX0035 and AMX0114.
What is Amylyx Pharmaceuticals, Inc.'s lead drug candidate?
Amylyx Pharmaceuticals, Inc.'s most advanced tracked candidate is AMX0035 (Phase 2) for Wolfram Syndrome.
What is Amylyx Pharmaceuticals, Inc.'s next catalyst?
Amylyx Pharmaceuticals, Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy a" — expected February 1, 2027.
Who is the CEO of Amylyx Pharmaceuticals, Inc.?
Mr. Joshua B. Cohen is the chief executive officer of Amylyx Pharmaceuticals, Inc. (AMLX).
Where is Amylyx Pharmaceuticals, Inc. headquartered?
Amylyx Pharmaceuticals, Inc. (AMLX) is headquartered in Cambridge, MA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.